Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harvinder S Virk

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
F1000Research|October 19, 2023
YCharOS open antibody characterisation data: Lessons learned and progress madeMichael S Biddle, Harvinder S Virk
Nature|August 15, 2023
Heed a decade of calls for antibody validationRichard A Kahn, Harvinder S Virk, Peter S McPherson
The Open Respiratory Medicine Journal|June 5, 2023
Lack of Benefit of High Flow Nasal Oxygen Therapy as Ceiling of Treatment for Severe COVID-19 Pneumonitis in Elderly Frail Patients: A Single Centre Observational StudyFatema Merchant, Akash Mavilakandy, Harvinder S Virk, et al.
British Journal of Pharmacology|March 31, 2021
TGFβ1 induces resistance of human lung myofibroblasts to cell death via down-regulation of TRPA1 channelsHarvinder S Virk, Michael S Biddle, Dawn T Smallwood, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2023
Scaling of an antibody validation procedure enables quantification of antibody performance in major research applicationsRiham Ayoubi, Joel Ryan, Michael S Biddle, et al.
Nature Protocols|December 17, 2024
A consensus platform for antibody characterizationRiham Ayoubi, Joel Ryan, Sara Gonzalez Bolivar, et al.
ERJ Open Research|October 1, 2025
Sex-specific genetic effects on susceptibility to idiopathic pulmonary fibrosisOlivia C Leavy, Anne F Goemans, Tamara Hernandez-Beeftink, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Genome-wide SNP-sex interaction analysis of susceptibility to idiopathic pulmonary fibrosisOlivia C Leavy, Anne F Goemans, Amy D Stockwell, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
F1000Research|October 19, 2023
YCharOS open antibody characterisation data: Lessons learned and progress madeMichael S Biddle, Harvinder S Virk
Nature|August 15, 2023
Heed a decade of calls for antibody validationRichard A Kahn, Harvinder S Virk, Peter S McPherson
The Open Respiratory Medicine Journal|June 5, 2023
Lack of Benefit of High Flow Nasal Oxygen Therapy as Ceiling of Treatment for Severe COVID-19 Pneumonitis in Elderly Frail Patients: A Single Centre Observational StudyFatema Merchant, Akash Mavilakandy, Harvinder S Virk, et al.
British Journal of Pharmacology|March 31, 2021
TGFβ1 induces resistance of human lung myofibroblasts to cell death via down-regulation of TRPA1 channelsHarvinder S Virk, Michael S Biddle, Dawn T Smallwood, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2023
Scaling of an antibody validation procedure enables quantification of antibody performance in major research applicationsRiham Ayoubi, Joel Ryan, Michael S Biddle, et al.
Nature Protocols|December 17, 2024
A consensus platform for antibody characterizationRiham Ayoubi, Joel Ryan, Sara Gonzalez Bolivar, et al.
ERJ Open Research|October 1, 2025
Sex-specific genetic effects on susceptibility to idiopathic pulmonary fibrosisOlivia C Leavy, Anne F Goemans, Tamara Hernandez-Beeftink, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Genome-wide SNP-sex interaction analysis of susceptibility to idiopathic pulmonary fibrosisOlivia C Leavy, Anne F Goemans, Amy D Stockwell, et al.
Pageof 1